# News

## July 15, 2026
**Cellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executives**  
New chief strategy officer and chief marketing officer join to help lead the company’s next phase of growth at the frontier of AI and biology.

## May 11, 2026
**CEO Perspective: A defining moment for Cellular Intelligence**  
We have entered into an agreement with Novo Nordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease.

## May 11, 2026
**Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson’s Cell Therapy**  
Cellular Intelligence has secured global rights to Novo Nordisk’s Parkinson’s program, a clinical-stage allogeneic cell therapy for Parkinson's disease with FDA Fast Track Designation.

## January 7, 2026
**Somite Becomes Cellular Intelligence, as It Builds the First Universal Virtual Cell-Signaling Model**  
New white paper details key technical milestones and validation of the company’s proprietary, capsule-based platform to accelerate breakthroughs across human health.

## August 20, 2025
**Somite.ai announces strategic investment from AMD Ventures to accelerate foundation models for cell therapy**  
Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures.

## May 13, 2025
**Somite raises over $47M Series A to revolutionize cell therapy with foundation models**  
Somite builds foundation models for human stem cells. We’ve just raised over $47M in Series A funding led by Khosla Ventures to accelerate development of DeltaStem, our foundation model to produce any cell type for any person.